Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut Microecology Changes with Vedolizumab in Ulcerative Colitis
NCT05481619Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2021
- Primary completion
- Jan 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of vedolizumab in ulcerative colitis (UC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Remission rate of patients at 1 year. Started Jan 2021; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05481619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481619.